MTIG
@MTIG_News
Followers
4K
Following
344
Statuses
2K
MTIG is dedicated to enhancing the regulatory, investment, and commercial environment to accelerate microbiome therapeutic drug product development.
Joined August 2019
.@FreyaBioscience’s immunotherapies aim to address immune drivers underlying a range of reproductive system conditions including IVF & natural conception, endometriosis infertility, preterm birth, and more. More info:
0
0
0
Join the Rebiotix, a Ferring Company, Stool Donor Program and help make a difference in the lives of patients battling recurrent C. difficile infections, and other debilitating diseases!
0
0
0
The human #microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources. Learn more:
0
0
0
.@BiomeSense developed the first AI-enabled technology platform for reliable, longitudinal, and low-cost generation & analysis of #microbiome data. Learn more about their mission to unlock the microbiome’s full personalized medicine potential here:
0
0
1
Alveolus' proprietary resMIT platform delivers safe, targeted bacteria directly to the lungs to address fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation indications (NCFBE, COPD). Learn more here: [link]
0
0
0
RT @MaaT_Pharma: Hervé Affagard @HAffagard presenting the competition global landscape for #microbiome companies and describing late-stage…
0
3
0
RT @MaaT_Pharma: 📅 [#EVENT] - Join Jonathan CHRIQUI, Chief Business Officer of MaaT Pharma, at the 9th Annual Microbiome Movement Summit ev…
0
3
0
RT @MaaT_Pharma: 📅 [#EVENT] – Join Alexandre Kiss, Europe Medical Advisor for Oncology and Hematology at MaaT Pharma, at the 17th “Journée…
0
4
0
RT @MaaT_Pharma: 📄[Press release] – MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033…
0
4
0
.@MaaT_Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
0
0
1
.@MaaT_Pharma 's MaaT013 has the potential to be the first approved third-line treatment option & transform the survival outcomes and redefine long-term prospects for approximately 3,000 third-line GI-aGvHD patients per year in the U.S., Canada & Europe.
0
4
5
In December 2024, the US FDA granted Breakthrough Therapy designation to @Serestx's SER-155 for reduction of bloodstream infections in adults undergoing allo-HSCT. Learn more about SER-155 here:
0
0
0
#Microbiome therapeutics hold significant therapeutic potential to prevent, treat, or cure a wide variety of diseases or conditions associated with the microbiome. Learn about the differences between LBP's and probiotic supplements here:
0
0
0
Congrats to @MaaT_Pharma on positive topline results from their Ph 3 study of MaaT013 in #aGvHD! The study met its primary endpoint w/ a significant GI response rate of 62% and demonstrates the unprecedented efficacy of MaaT013 as third-line treatment.
0
2
3
.@SeresTX Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
0
0
1
RT @MaaT_Pharma: 🔎 With 30-50% of patients developing aGvHD post-transplant, the current treatments fall short. Dr. @Afschauw discusses the…
0
3
0
RT @MaaT_Pharma: 📄 [Press release] – MaaT Pharma is proud to announce positive Phase 3 results evaluating MaaT013 in treating acute Graft-v…
0
5
0
.@MaaT_Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
0
5
7